This clinical trial in 20 patients commenced in June with last data collection estimated to occur in early 2025.
The trial is funded by private company, BellaSeno, which was founded by Prof. Dietmar Hutmacher from the Queensland University of Technology.
BellaSeno is a medtech company developing absorbable scaffolds using additive manufacturing technologies. The company is based in Leipzig, Germany.
The patented porous scaffolding for the breast is made from absorbable polycaprolactone which is then filled with injected autologous fat graft harvested via liposuction.
The key patent covering the platform has been exclusively licensed from Technical University, Munich.
Interestingly, another 20 patient trial was due to commence in Victoria last month, testing a “volumetric bioabsorbable scaffold with Vital Autologous fat graft for post-mastectomy patients”.
This breast scaffold uses poly-4-hydroxybutyrate (P4HB). The trial is being funded by medtech giant, Becton Dickinson.
PNV - Banter and General Comments, page-8049
-
- There are more pages in this discussion • 4,395 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
-0.090(3.57%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $2.49 | $2.50 | $2.43 | $2.311M | 940.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17100 | $2.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.45 | 5973 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |